Frontiers in Pharmacology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 13, 2023
Background:
The
potential
benefits
of
intervention
with
empagliflozin
or
dapagliflozin
for
patients
heart
failure
preserved
ejection
fraction
(HFpEF)
were
first
demonstrated
in
the
EMPEROR-Preserved
and
DELIVER
studies.
However,
cost-effectiveness
this
(empagliflozin
dapagliflozin)
is
yet
to
be
established.
Methods:
In
context
Chinese
healthcare,
a
Markov
model
was
proposed,
which
incorporates
clinical
outcomes
from
studies,
predict
utility
costs
over
lifetime.
time
horizon
20
years,
5%
discount
rate
applied
utilities.
incremental
ratio
(ICER)
threshold
against
willingness
pay
(WTP)
set
as
primary
outcome.
robustness
decision
evaluated
using
sensitivity
analyses.
Results:
After
simulated
20-year
lifetime,
72-year-old
patient
HFpEF
group
(empagliflozin)
showed
an
increase
0.44
quality-adjusted
life
years
(QALYs)
$1,623.58
ICER
$3,691.56
per
QALY,
lower
than
WTP
$12,032.10
QALY.
A
(dapagliflozin)
0.34
QALYs
$2,002.13
$5,907.79
One-way
analyses
that
cardiovascular
(CV)
mortality
comparator
groups
most
sensitive
decision.
Cost-effectiveness
67.9%
62.2%
1000
Monte
Carlo
simulations,
respectively.
Conclusion:
interventions
more
cost-effective
comparators.
Our
study
has
provided
quantitative
evaluation
such
lifetime
model.
BACKGROUND:
The
American
Heart
Association
(AHA),
in
conjunction
with
the
National
Institutes
of
Health,
annually
reports
most
up-to-date
statistics
related
to
heart
disease,
stroke,
and
cardiovascular
risk
factors,
including
core
health
behaviors
(smoking,
physical
activity,
nutrition,
sleep,
obesity)
factors
(cholesterol,
blood
pressure,
glucose
control,
metabolic
syndrome)
that
contribute
health.
AHA
Disease
Stroke
Statistical
Update
presents
latest
data
on
a
range
major
clinical
circulatory
disease
conditions
(including
brain
health,
complications
pregnancy,
kidney
congenital
rhythm
disorders,
sudden
cardiac
arrest,
subclinical
atherosclerosis,
coronary
cardiomyopathy,
failure,
valvular
venous
thromboembolism,
peripheral
artery
disease)
associated
outcomes
quality
care,
procedures,
economic
costs).
METHODS:
AHA,
through
its
Epidemiology
Prevention
Statistics
Committee,
continuously
monitors
evaluates
sources
stroke
United
States
globally
provide
current
information
available
annual
review
published
literature
year
before
writing.
2024
is
product
full
year’s
worth
effort
2023
by
dedicated
volunteer
clinicians
scientists,
committed
government
professionals,
staff
members.
strives
further
understand
help
heal
problems
inflicted
structural
racism,
public
crisis
can
significantly
damage
mental
perpetuate
disparities
access
education,
income,
housing,
several
other
vital
healthy
lives.
This
edition
includes
additional
global
data,
as
well
monitoring
benefits
population,
an
enhanced
focus
equity
across
key
domains.
RESULTS:
Each
chapters
focuses
different
topic
statistics.
CONCLUSIONS:
represents
critical
resource
for
lay
public,
policymakers,
media
clinicians,
care
administrators,
researchers,
advocates,
others
seeking
best
these
conditions.
JAMA Cardiology,
Год журнала:
2023,
Номер
8(11), С. 1041 - 1041
Опубликована: Сен. 27, 2023
The
US
Food
and
Drug
Administration
expanded
labeling
of
sacubitril-valsartan
from
the
treatment
patients
with
chronic
heart
failure
(HF)
reduced
ejection
fraction
(EF)
to
all
HF,
noting
greatest
benefits
in
those
below-normal
EF.
However,
upper
bound
below
normal
is
not
clearly
defined,
value
determinations
across
a
broader
EF
range
are
unknown.
ESC Heart Failure,
Год журнала:
2024,
Номер
11(3), С. 1341 - 1351
Опубликована: Фев. 6, 2024
The
purpose
of
this
study
was
to
systematically
review
the
development,
performance,
and
applicability
prognostic
models
developed
for
predicting
poor
events
in
patients
with
heart
failure
preserved
ejection
fraction
(HFpEF).
Databases
including
Embase,
PubMed,
Web
Science
Core
Collection,
Cochrane
Library,
China
National
Knowledge
Infrastructure,
Wan
Fang,
Wei
Pu,
Biological
Medicine
were
queried
from
their
respective
dates
inception
1
June
2023,
examine
multivariate
prediction
HFpEF.
Both
forward
backward
citations
all
studies
included
our
analysis.
Two
researchers
individually
used
Critical
Appraisal
Data
Extraction
Systematic
Reviews
Prediction
Modelling
Studies
(CHARMS)
checklist
extract
data
assess
quality
using
Predictive
Mode
Bias
Risk
Assessment
Tool
(PROBAST).
Among
6897
screened,
16
derived
and/or
validated
a
total
39
models.
sample
size
ranges
model
internal
validation,
external
validation
are
119
5988,
152
1000,
30
5957,
respectively.
most
frequently
employed
modelling
technique
Cox
proportional
hazards
regression.
Six
(37.50%)
conducted
models;
bootstrap
k-fold
cross-validation
commonly
methods
Ten
these
(25.64%)
externally,
reported
c-statistic
set
ranging
0.70
0.96,
while
remaining
await
validation.
MEDIA
echo
score
I-PRESERVE-sudden
cardiac
death
mode
have
been
externally
multiple
cohorts,
results
consistently
show
good
predictive
performance.
predictors
identified
among
age,
n-terminal
pro-brain
natriuretic
peptide,
fraction,
albumin,
hospital
stay
last
5
months
owing
failure.
All
predictor
domains
outcome
at
low
risk
bias,
high
or
unclear
bias
due
underreporting
area
did
not
evaluate
clinical
utility
outcomes
HFpEF
showed
discriminatory
ability
but
generalization
remain
uncertain
differences
between
models,
lack
application
studies.
Future
should
improve
methodological
development
conduct
Journal of the American Heart Association,
Год журнала:
2024,
Номер
13(5)
Опубликована: Фев. 23, 2024
The
sodium
glucose
cotransporter-2
inhibitors
are
guideline-recommended
to
treat
heart
failure
across
the
spectrum
of
left
ventricular
ejection
fraction;
however,
economic
evaluations
adding
standard
care
in
chronic
a
broad
fraction
range
lacking.
Circulation Heart Failure,
Год журнала:
2023,
Номер
16(12)
Опубликована: Ноя. 6, 2023
The
STRONG-HF
trial
(Safety,
Tolerability
and
Efficacy
of
Up-Titration
Guideline-Directed
Medical
Therapies
for
Acute
Heart
Failure)
demonstrated
substantial
reductions
in
the
composite
mortality
morbidity
over
6
months
among
hospitalized
patients
with
heart
failure
(HF)
who
were
randomized
to
intensive
guideline-directed
medical
therapy
(GDMT)
optimization
compared
usual
care.
Whether
an
GDMT
program
would
be
cost-effective
HF
reduced
ejection
fraction
is
unknown.
